Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Rating of “Hold” from Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been assigned an average rating of “Hold” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. Nine research analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company.

A number of equities analysts have recently weighed in on ZLDPF shares. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Zacks Research upgraded Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a report on Friday, September 11th. Finally, Barclays lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th.

Zealand Pharma A/S Stock Down 12.7%

Zealand Pharma A/S stock opened at $38.10 on Friday. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of 6.32 and a beta of 0.95. The company’s 50 day simple moving average is $46.78 and its 200 day simple moving average is $46.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. Zealand Pharma A/S has a fifty-two week low of $35.93 and a fifty-two week high of $83.12.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.